Financings Of The Fortnight: Do Larger Series A Rounds Mean Less Successful Exits?
This article was originally published in The Pink Sheet Daily
Executive Summary
A five-year review of Series A financings finds no negative correlation between the size of an A round and the likelihood of an investor exit. Plus news on recent financings by Veracyte, Calithera Biosciences, Spark Therapeutics and Versant Ventures.
You may also be interested in...
CHOP Commits $50 Million To Gene Therapy Spin-Out Spark Therapeutics
Non-profit hospital spins out its first start-up, which will house one program to address a heritable form of blindness, another to treat hemophilia B.
With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders
The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.
Veracyte: How To Build A Molecular Cytology Company
Veracyte has launched a complex molecular diagnostic test in thyroid in record time and with impressive capital efficiency. It could be a model for high-value diagnostics, especially if the company can successfully adopt its approach in a broader market.